코로나바이러스감염증-19로 입원한 환자들에 대한 아연의 임상적 효과: 체계적 문헌고찰 및 메타분석
Clinical Effects of Zinc Supplementation in Patients Hospitalized with COVID-19: A Systematic Review and Meta-analysis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Zinc is known for modulating antiviral and antibacterial immunity and regulating inflammatory response. This study aimed to examine the effect of zinc supplementation on clinical outcomes of hospitalized COVID-19 patients through systematic literature review and meta-analysis. Methods: PubMed/Medline, Embase, and Cochrane library databases were searched for studies comparing zinc supplement group versus control group for clinical outcomes of COVID-19 up to November 3, 2020. The search results were updated on February 9, 2021. The meta-analysis was performed by RevMan 5.4 software. Results: Total 4 studies were included in this systematic review. The zinc administered group had a significantly lower mortality rate compared with the control group (odds ratio [OR] 0.63, 95% confidence interval [95% CI] 0.53-0.75, p<0.001), with significantly higher discharge rate (OR 1.32, 95% Cl 1.15-1.52, p<0.001). However, there were no significant differences in the intensive care unit admission rate (OR 1.07, 95% Cl 0.26-4.48, p=0.92), mechanical ventilation rate (OR 0.80, 95% Cl 0.45-1.41, p=0.44), and length of hospital stay (mean difference 0.75, 95% Cl −0.64 to 2.13, p=0.29) between the two groups. Conclusion: The meta-analysis of zinc administration showed positive clinical effects on the discharge rate and mortality of COVID-19 hospitalized patients. However, large-scale randomized controlled trial should be conducted for zinc to be considered as one of the adjuvant treatments.
Abstract
Background: Zinc is known for modulating antiviral and antibacterial immunity and regulating inflammatory response. This study aimed to examine the effect of zinc supplementation on clinical outcomes of hospitalized COVID-19 patients through systematic literature review and meta-analysis. Methods: PubMed/Medline, Embase, and Cochrane library databases were searched for studies comparing zinc supplement group versus control group for clinical outcomes of COVID-19 up to November 3, 2020. The search results were updated on February 9, 2021. The meta-analysis was performed by RevMan 5.4 software. Results: Total 4 studies were included in this systematic review. The zinc administered group had a significantly lower mortality rate compared with the control group (odds ratio [OR] 0.63, 95% confidence interval [95% CI] 0.53-0.75, p<0.001), with significantly higher discharge rate (OR 1.32, 95% Cl 1.15-1.52, p<0.001). However, there were no significant differences in the intensive care unit admission rate (OR 1.07, 95% Cl 0.26-4.48, p=0.92), mechanical ventilation rate (OR 0.80, 95% Cl 0.45-1.41, p=0.44), and length of hospital stay (mean difference 0.75, 95% Cl −0.64 to 2.13, p=0.29) between the two groups. Conclusion: The meta-analysis of zinc administration showed positive clinical effects on the discharge rate and mortality of COVID-19 hospitalized patients. However, large-scale randomized controlled trial should be conducted for zinc to be considered as one of the adjuvant treatments.
참고문헌 (29)
- "Coronavirus disease (COVID-19) pandemic"[URL]
- Bimonte S, "Potential antiviral drugs for SARS-Cov-2 treatment : Preclinical findings and ongoing clinical research", In Vivo, 34(3Suppl), pp.1597~1602 (2020)
- Prasad AS, "Molecular, Genetic, and Nutritional Aspects of Major and Trace Minerals", pp.241~260 (2017)
- Gammoh NZ, "Zinc in infection and inflammation", Nutrients, 9(6), pp.624~ (2017)
- Wessels I, "Zinc as a gatekeeper of immune function", Nutrients, 9(12), pp.1286~ (2017)
- Acevedo-Murillo JA, "Zinc supplementation promotes a Th1 response and improves clinical symptoms in fewer hours in children with pneumonia younger than 5 years old. a randomized controlled clinical trial", Front Pediatr, 7, pp.431~ (2019)
- Barnett JB, "Low zinc status: a new risk factor for pneumonia in the elderly?", Nutr Rev, 68(1), pp.30~37 (2010)
- Xue J, "Chloroquine is a zinc ionophore", PLoS One, 9(10), pp.e109180~ (2014)
- Read SA, "The role of zinc in antiviral immunity", Adv Nutr, 10(4), pp.696~710 (2019)
- te Velthuis AJ, "Zn(2+)inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture", PLoS Pathog, 6(11), pp.e1001176~ (2010)
- Awotiwon AA, "Zinc supplementation for the treatment of measles in children", Cochrane Database Syst Rev, 6(6), pp.CD011177~ (2017)
- Bobat R, "Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa : a randomised double-blind placebo-controlled trial", Lancet, 366(9500), pp.1862~1867 (2005)
- Zeng L, "Efficacy and safety of zinc supplementation for adults, children and pregnant women with HIV infection: systematic review", Trop Med Int Health, 16(12), pp.1474~1482 (2011)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement", BMJ, 339, pp.b2535~ (2009)
- Higgins JP, "The cochrane collaboration's tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses" (2011)[URL]
- 임선미, "근거수준별 문헌의 질 평가 도구", 대한의사협회지, 54(4), pp.419~429 (2011), 대한의사협회
- Luo D, "Optimally estimating the sample mean from the sample size, median, mid-range, and", or mid-quartile range, 2018, pp.27(6), 1785~1805
- Yao JS, "The minimal effect of zinc on the survival of hospitalized patients with COVID-19 : an observational study", Chest, 159(1), pp.108~111 (2021)
- Frontera JA, "Treatment with zinc is associated with reduced in-hospital mortality among COVID-19patients : a multi-center cohort study", Res Sq (2020)
- Carlucci PM, "Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients", J Med Microbiol, 69(10), pp.1228~1234 (2020)
- Abd-Elsalam S, "Do zinc supplements enhance the clinical efficacy of Hydroxychloroquine?: a randomized, multicenter trial", Biol Trace Elem Res, pp.1~5 (2020)
- Lassi ZS, "Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months", Cochrane Database Syst Rev, 12(12), pp.CD005978~ (2016)
- Gao YD, "Risk factors for severe and critically ill COVID-19 patients : a review", Allergy, 76(2), pp.428~455 (2021)
- Shittu MO, "Improving the efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 may require zinc additives-a better synergy for future COVID-19 clinical trials", Infez Med, 28(2), pp.192~197 (2020)
- Wang L, "Efficacy of zinc given as an adjunct to the treatment of severe pneumonia: a meta-analysis of randomized, double-blind and placebo-controlled trials", Clin Respir J, 12(3), pp.857~864 (2018)
- Singh M, "Zinc for the common cold", Cochrane Database Syst Rev, (6), pp.CD001364~ (2013)
- Hemilä H, "Zinc lozenges may shorten the duration of colds : a systematic review", Open Respir Med J, 5, pp.51~58 (2011)